‘I got a little taste of it': Woman battles US$20,000 hospital bill after bat flies into her mouth
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
CVRx (CVRX) Q2 Revenue Jumps 15%
Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
CBC
2 hours ago
- CBC
Lyme disease more common as warmer summers bring more ticks
Singer Justin Timberlake is the latest celebrity to announce he's been battling Lyme disease, but experts say cases of the tick-borne illness are on the rise in Canada, too, largely because warmer summers have extended tick season.
Globe and Mail
6 hours ago
- Globe and Mail
EULA Home Care Agency Reaffirms Commitment to Provide Senior Home Care in Harrisburg
Smiling together, a caregiver and senior share a warm moment over a medication check—capturing the heart of EULA Home Care Agency Reaffirms Commitment to Provide Senior Home Care in Harrisburg. This image reflects the trust, compassion, and personalized support EULA delivers to every family they serve in the Harrisburg community. EULA Home Care Agency reaffirms its commitment to senior care in Harrisburg, NC, ensuring aging residents have access to compassionate, personalized in-home support. The agency's professional caregivers assist with daily tasks, mobility, and companionship, helping seniors live independently while giving families peace of mind. With a growing senior population, EULA continues to be a trusted resource for reliable, dignified care rooted in community values. Harrisburg, NC - EULA Home Care Agency, a trusted provider of in-home senior care services, today announced its continued and unwavering commitment to the families and elderly residents of Harrisburg, NC. The agency reaffirms its mission to deliver high-quality, compassionate care, enabling seniors to live comfortably and independently in their own homes. This reaffirmation comes at a crucial time when accessible and reliable care is more important than ever for the community. One of the primary benefits of the services offered by EULA Home Care Agency is the creation of personalized care plans tailored to each individual's unique needs and requirements. Recognizing that every senior has different requirements, the agency's professional caregivers provide support ranging from assistance with daily living activities, such as bathing and meal preparation, to medication reminders and mobility support. This customized approach to senior care in Harrisburg, NC, not only ensures the physical safety and well-being of clients but also promotes a greater sense of independence and dignity. Furthermore, the agency provides invaluable peace of mind for families. Entrusting the care of a loved one to a professional can be a difficult decision, but EULA Home Care Agency alleviates this stress by offering reliable, vetted, and compassionate caregivers. Families can rest assured that their senior relatives are receiving exceptional Harrisburg senior home care, allowing family caregivers to get much-needed respite, reduce burnout, and spend more quality time with their loved ones without the constant pressure of caregiving responsibilities. "Our mission has always been deeply rooted in the community we serve," said Davetta Williams, founder of EULA Home Care Agency. "We believe every senior deserves to age with dignity and grace in the comfort of their own home. We are here to ensure that families in Harrisburg know they have a reliable partner to turn to for compassionate and skilled care, making the aging process a smoother and more positive experience for everyone involved." As the senior population in the region continues to grow, the need for dependable in-home care services has become increasingly evident. EULA Home Care Agency addresses this demand by focusing on a holistic approach that supports not only the physical health of seniors but also their emotional and social well-being. By providing companionship and fostering genuine connections, their caregivers help combat the loneliness and isolation that many seniors can experience. EULA Home Care Agency remains dedicated to being a pillar of support for the Harrisburg community. By continuing to offer accessible and professional services, the agency ensures that local families have a trusted resource for senior care. Families seeking more information about the services provided are encouraged to visit the agency's website or call their office directly to schedule a complimentary consultation. For more information about EULA Home Care Agency and their senior home care in Harrisburg, NC, please visit their website at About EULA Home Care Agency: EULA Home Care Agency is a premier provider of non-medical, in-home care services for seniors in Harrisburg, NC, and the surrounding areas. Founded by Davetta Williams, the agency is dedicated to delivering compassionate, professional, and personalized care that enables seniors to live safely and comfortably in their own homes. Media Contact Company Name: EULA Home Care Agency Contact Person: Davetta Williams Email: Send Email Phone: +1 704 549 8300 Address: 8430 University Executive Park Dr Suite 606 City: Charlotte State: NC Country: United States Website:
